1. Search Result
Search Result
Results for "

cGAMP

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

8

Natural
Products

2

Recombinant Proteins

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12512
    cGAMP
    15+ Cited Publications

    Cyclic GMP-AMP; 3',3'-cGAMP

    STING Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP
  • HY-110385
    cGAMP disodium
    15+ Cited Publications

    Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium

    STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP disodium
  • HY-110385A
    cGAMP diammonium
    15+ Cited Publications

    Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium

    STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP diammonium
  • HY-100564
    2',3'-cGAMP
    Maximum Cited Publications
    24 Publications Verification

    2'-3'-cyclic GMP-AMP

    Endogenous Metabolite STING IFNAR Metabolic Disease
    2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm .
    2',3'-cGAMP
  • HY-100564A
    2',3'-cGAMP sodium
    Maximum Cited Publications
    24 Publications Verification

    2'-3'-cyclic GMP-AMP sodium

    Endogenous Metabolite STING IFNAR Metabolic Disease
    2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm .
    2',3'-cGAMP sodium
  • HY-141550

    NF-κB Inflammation/Immunology
    BPK-25, an active acrylamide, promotes degradation of nucleosome remodeling and deacetylation (NuRD) complex proteins by a post-translational mechanism involving covalent protein engagement. BPK-25 inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP .
    BPK-25
  • HY-137709

    STING IFNAR Endogenous Metabolite Metabolic Disease
    2'2'-cGAMP, a synthetic CDN, binds STING in the immune response, inducing IFN-β. 2'2'-cGAMP binds weaker binding to STING than 2'3'-cGAMP (HY-100564) but stronger than other CDNs .
    2'2'-cGAMP
  • HY-141662

    STING Drug-Linker Conjugates for ADC Inflammation/Immunology Cancer
    2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases .
    2',3'-cGAMP-C2-PPA
  • HY-100564BS

    2'-3'-Cyclic GMP-AMP-d8 ammonium

    Isotope-Labeled Compounds Others
    2',3'-cGAMP-d8 (2'-3'-Cyclic GMP-AMP-d8) ammonium is deuterium labeled 2',3'-cGAMP (ammonium) .
    2',3'-cGAMP-d8 ammonium
  • HY-141663

    ADC Linker Cancer
    2',3'-cGAMP-C2-SH is a cyclic di-nucleotide (CDN) that can be conjugated to antibodies or antigen-binding fragments targeting specific antigens in the microenvironment of diseased cells or tissue .
    2',3'-cGAMP-C2-SH
  • HY-131454
    SR-717
    20+ Cited Publications

    STING Inflammation/Immunology Cancer
    SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
    SR-717
  • HY-131454A
    SR-717 free acid
    20+ Cited Publications

    STING Inflammation/Immunology Cancer
    SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
    SR-717 free acid
  • HY-172671

    STING Cancer
    STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
    STING agonist-43
  • HY-174136

    STING Inflammation/Immunology
    STING Degrader-2 (Compound SI-43) is a STING inhibitor and mutant-specific degrader. STING Degrader-2 can effectively inhibit cGAMP-induced STING activation and significantly reduce the release of IFN-β and CXCL-10. It inhibits the activity of STING by binding to two pockets of the STING dimer and induces proteasome-independent degradation of mutants STING S154 and STING M155 (DC50 values are 0.31 and 0.76 μM, respectively). STING Degrader-2 can be used to study STING-related autoimmune diseases .
    STING Degrader-2
  • HY-159857

    Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    Others
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-176708

    Phosphodiesterase (PDE) Cancer
    ISM5939 is an orally active and selective ENPP1 inhibitor with an IC50 of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity .
    ISM5939
  • HY-153398

    Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 .
    Enpp-1-IN-17
  • HY-141831

    Phosphodiesterase (PDE) Cancer
    STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity .
    STF-1084
  • HY-144168A

    STING Inflammation/Immunology
    STING agonist-8 dihydrochloride (compound 5-AB) is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells .
    STING agonist-8 dihydrochloride
  • HY-144168

    STING Inflammation/Immunology
    STING agonist-8 is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells (WO2021239068A1, compound 5-AB) .
    STING agonist-8
  • HY-175478

    Phosphodiesterase (PDE) STING Inflammation/Immunology Cancer
    Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the STING pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer .
    Enpp-1-IN-27
  • HY-138682
    STING-IN-2
    5+ Cited Publications

    STING Inflammation/Immunology
    STING-IN-2 (C-170) is a potent and covalent STING inhibitor. STING-IN-2 efficiently inhibits both mouse STING (mmSTING) and human STING (hsSTING). STING-IN-2 can be used for autoinflammatory disease research .
    STING-IN-2
  • HY-175047

    Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-26 (Compound 4e) is an ENPP1 inhibitor with an IC50 of 0.188 μM. Enpp-1-IN-26 enhances IFN-β expression in vivo by preventing ENPP1 from hydrolyzing cGAMP. Enpp-1-IN-26 can be used in the research of metastatic breast cancer .
    Enpp-1-IN-26
  • HY-175167

    STING Inflammation/Immunology
    diABZI-i is a orthosteric STING inhibitor. diABZI-i significantly inhibits cGAMP-induced IFNβ in PBMCs with an IC50 of 49 nM. diABZI-i also activates V155M SAVI constitutive signaling in STING V155M THP-1 cells model with potent agonism (EC50: 17  nM). diABZI-i can be used for monogenic autoinflammatory disease like SAVI disease research .
    diABZI-i
  • HY-176828

    Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-28 is a ENPP1 inhibitor at the molecular and cellular levels, with IC50 values of 0.188 µM and 0.732 µM, respectively. Enpp-1-IN-28 upgrades the expression levels of IFN-β in vivo by preventing the ENPP1 from hydrolyzing the cGAMP to stimulate a more potent innate immune response. Enpp-1-IN-28 can be used for the study of metastatic breast cancer .
    Enpp-1-IN-28
  • HY-157214

    STING Molecular Glues Cancer
    NVS-STG2 is a molecular glue that targets STINGcGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .
    NVS-STG2
  • HY-155457

    Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .
    Enpp-1-IN-19
  • HY-168491

    Phosphodiesterase (PDE) STING PD-1/PD-L1 Cancer
    Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .
    Enpp-1-IN-25
  • HY-163749

    STING Inflammation/Immunology
    STING-IN-8 (Compound 15b) emerges as a potent stimulator of interferon gene (STING) inhibitor with an IC50 value of 0.121 μM in human and an IC50 value of 0.033 μM in mouse. STING-IN-8 inhibits MSA-2 (HY-136927) or 2’, 3’ -cGAMP (HY-100564)-stimulated STING signaling and suppresses immune-inflammatory cytokine levels in both human and murine cells. STING-IN-8 is promising for research in the field of STING-associated inflammatory and autoimmune diseases .
    STING-IN-8
  • HY-170362

    Cyclic GMP-AMP Synthase Inflammation/Immunology
    cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active
    cGAS-IN-4
  • HY-113469A
    Cyclic GMP sodium
    1 Publications Verification

    Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium
  • HY-113469
    Cyclic GMP
    1 Publications Verification

    Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP
  • HY-113469B
    Cyclic GMP (TBAOH)
    1 Publications Verification

    Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP) TBAOH, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP TBAOH occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP (TBAOH)
  • HY-W767865

    Isotope-Labeled Compounds Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP sodium- 13C5 is the 13C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium-13C5
  • HY-113469AR

    Reference Standards Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP sodium (Standard) is the analytical standard of Cyclic GMP sodium (HY-113469A). This product is intended for research and analytical applications. Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium (Standard)
  • HY-113469R

    Endogenous Metabolite Reference Standards Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP (Standard)
  • HY-W654000

    Guanosine 3',5'-cyclic-13C,15N2 monophosphate

    Isotope-Labeled Compounds Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP- 13C, 15N2 is 13C and 15N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP-13C,15N2
  • HY-174170

    STING Cancer
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide (compound 4) is a STING agonist containing a key amide benzimidazole (ABZI) component and shows reproducible inhibition of 3H-cGAMP binding to STING with an apparent inhibition constant IC50 of 14 μM. (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide can be used for tumor research .
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: